ArticleAdvances in therapy2026

Summary of Research: Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trials (the ENHANCE Trials).

Antonio Anzueto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.